Solvay misses out on swine flu contract; CSL plans to boost seasonal vax production;

Swine Flu

Shares of Solvay dipped after the company announced earlier in the week that it had missed out on a contract to supply the Dutch government with H1N1 vaccine. Solvay couldn't meet the government's delivery schedule. The Dutch government bought 34 million doses of swine flu vaccine from other suppliers. Report

AVI Biopharma has struck a deal with the U.S. Defense Threat Reduction Agency to develop a new swine flu vaccine based on its RNA technology. Report

Hualan Biological Engineering says it has produced China's first swine flu vaccine, which is slated to hit the market in September. Story

Vaccine market

Australia's CSL says that it may double next year's shipments of seasonal flu vaccine after selling out this season. Story

The therapeutic vaccine developer Cel-Sci says it is raising $5 million in badly-needed funds from an institutional investor. Report

The USDA has approved a new vaccine for canine influenza. Intervet/Schering-Plough Animal Health says it will continue to supply data on the vaccine during the conditional licensing period. Story

Vaccine Research

Novavax has published preclinical study results that supported the clinical development of the company's investigational VLP vaccine against the H3N2, H1N1 and B influenza strains. Release

A new vaccine for African Horse Sickness has shown promising results in new research. The virus kills up to 90 percent of the horses that are exposed to it. Story

ImmunoCellular Therapeutics has struck a deal with Formatech for the manufacture of IMUC's cancer stem cell vaccine product candidate, ICT-121, for an upcoming clinical trial. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.